Close Menu

circulating tumor DNA

The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.

The company said it is on track to complete a clinical validation by the end of next year, after which it would launch its assay for clinical use.

The group believes that being able to track ctDNA changes down to the lowest possible levels may be necessary for liquid biopsy to monitor treatment in early-stage cancers.

In Science this week: CRISPR gene editing and single-cell RNA sequencing together form a framework for studying genetic interactions, and more.

The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.

The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.

Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.

The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.

The firm claims that its liquid biopsy platform can identify mutations in patient samples at femtogram-level concentrations.

Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.

Pages

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.